The Pharmaceutical Benefits Scheme
MMIMediumAnswer the question
The Pharmaceutical Benefits Scheme
How does the Pharmaceutical Benefits Scheme (PBS) work, and what ethical questions arise when a new high-cost medicine is considered for listing?
What is the role of the Pharmaceutical Benefits Advisory Committee (PBAC)?
How are co-payments set, and what does the PBS Safety Net offer?
Should the PBS list every drug TGA-approved, regardless of cost-effectiveness?
Speak it out loud and we'll type it for you (free), or type your own notes — then mark yourself below.
- Four pillars: autonomy, beneficence, non-maleficence, justice.
- Name the conflict → weigh both sides → gather more info → safe, patient-centred action.
What strong answers doReveal the benchmark
Hidden so they don't bias your answer. Score yourself first, then reveal them to compare.
- The PBS subsidises around 5,000 medicines after the PBAC reviews cost-effectiveness using QALYs; in 2024 the general co-payment was around $31.60 and the concession about $7.70, and the Safety Net caps annual out-of-pocket costs once the threshold is met. Check the current figures before your interview.
- The ethical tension is that rationing by cost-effectiveness can deny access to TGA-approved drugs; recent debates include CFTR modulators for cystic fibrosis, CAR-T therapies, and GLP-1 agonists for obesity versus a diabetes-only listing.
- Acknowledge opportunity cost, since every listing displaces spending elsewhere, while crediting the PBAC's transparent process and willingness-to-pay thresholds as world-leading even when individual decisions feel painful.
Mark yourself
Score each skill against the rubric, then add a line of evidence. Scale:
Healthcare Knowledge
0/3Understands PBS mechanics and PBAC role
Ethical Awareness
0/3Grapples with rationing and opportunity cost
Critical Thinking
0/3Weighs individual access against population benefit
Insight
0/3Mentions specific contested listings